Skip to content
10-Q

Quarterly Report

X4 Pharmaceuticals, Inc XFOR

0001501697-26-000040

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 94.32M sh
Shares Diluted Q1 2026 · Mar 31, 2026 126.29M sh
Shares Diluted Q1 2026 · Mar 31, 2025 6.87M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$12.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $216.91M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $217.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 $168.45M
Stockholders Equity Q1 2026 · Dec 31, 2025 $186.29M
Stockholders Equity Q1 2026 · Mar 31, 2025 $22.94M
Stockholders Equity Q1 2026 · Dec 31, 2024 $22.15M
Current Liabilities Q1 2026 · Mar 31, 2026 $23.77M
Current Liabilities Q1 2026 · Dec 31, 2025 $25.76M
Total Liabilities Q1 2026 · Mar 31, 2026 $101.83M
Total Liabilities Q1 2026 · Dec 31, 2025 $104.17M
Current Assets Q1 2026 · Mar 31, 2026 $241.98M
Current Assets Q1 2026 · Dec 31, 2025 $261.58M
Total Assets Q1 2026 · Mar 31, 2026 $270.28M
Total Assets Q1 2026 · Dec 31, 2025 $290.46M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.16
Eps Diluted Q1 2026 · Mar 31, 2025 $0.04
Eps Basic Q1 2026 · Mar 31, 2026 −$0.16
Eps Basic Q1 2026 · Mar 31, 2025 $0.04
Sga Expense Q1 2026 · Mar 31, 2026 $6.97M
Sga Expense Q1 2026 · Mar 31, 2025 $15.02M
Rd Expense Q1 2026 · Mar 31, 2026 $15.45M
Rd Expense Q1 2026 · Mar 31, 2025 $18.51M
Net Income Q1 2026 · Mar 31, 2026 −$20.24M
Net Income Q1 2026 · Mar 31, 2025 $282K
Operating Income Q1 2026 · Mar 31, 2026 −$20.31M
Operating Income Q1 2026 · Mar 31, 2025 −$9.44M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $598K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $4.72M
Revenue Q1 2026 · Mar 31, 2026 $2.71M
Revenue Q1 2026 · Mar 31, 2025 $28.81M